Mechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events.
CTLA-4
PD-1
PD-L1
immune-related adverse events
myocarditis
Journal
JMA journal
ISSN: 2433-3298
Titre abrégé: JMA J
Pays: Japan
ID NLM: 101769797
Informations de publication
Date de publication:
15 Apr 2021
15 Apr 2021
Historique:
received:
01
01
2021
accepted:
15
01
2021
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
18
5
2021
Statut:
ppublish
Résumé
Onco-cardiology recently emerged as a novel discipline to provide effective cardioprotective care against cancer therapeutics-related cardiac adverse events (CAEs) and support the continuity of optimal cancer treatment. Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and dramatically improved outcomes in patients with advanced or refractory cancers. However, ICIs intrinsically stimulate systemic immune responses and can potentially induce a spectrum of immune-related adverse events (irAEs), which can affect any organs of the body. The manifestation of cardiac irAEs includes myocarditis, arrhythmias and conduction abnormalities, and pericardial diseases. Takotsubo-like cardiomyopathy is also included as a manifestation of ICI-related CAEs, but the pathophysiological relevance is unclear. Although the incidence is rare, ICI-related CAEs are life-threatening and potentially fatal. Elucidating pathophysiology and establishing management measures of ICI-related CAEs are one of the most urgent challenges in the field of onco-cardiology.
Identifiants
pubmed: 33997442
doi: 10.31662/jmaj.2021-0001
pmc: PMC8118963
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
91-98Informations de copyright
Copyright © Japan Medical Association.
Déclaration de conflit d'intérêts
H.A. has received trust research/joint research funding from Ono Pharmaceutical Co., Ltd., and honoraria for lecture from Daiichi Sankyo Co., Ltd., Bayer Yakuhin, Ltd., and Pfizer Japan Inc; I.K. has received honoraria for lecture from Ono Pharmaceutical Co., Ltd.
Références
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Circulation. 2007 Oct 30;116(18):2062-71
pubmed: 17938288
Immunity. 1995 Nov;3(5):541-7
pubmed: 7584144
Lancet Oncol. 2018 Sep;19(9):e447-e458
pubmed: 30191849
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Immunity. 1999 Aug;11(2):141-51
pubmed: 10485649
Nat Med. 2003 Dec;9(12):1477-83
pubmed: 14595408
Am J Cardiol. 2019 Apr 15;123(8):1351-1357
pubmed: 30765065
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Science. 2001 Jan 12;291(5502):319-22
pubmed: 11209085
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764
pubmed: 29567210
PLoS One. 2015 Apr 22;10(4):e0124059
pubmed: 25902191
J Immunother Cancer. 2016 Aug 16;4:50
pubmed: 27532025
J Am Heart Assoc. 2020 Jan 21;9(2):e013757
pubmed: 31960755
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Int Heart J. 2020 Sep 29;61(5):1070-1074
pubmed: 32921673
Eur J Immunol. 2003 Oct;33(10):2706-16
pubmed: 14515254
Cardiovasc Res. 2019 Apr 15;115(5):869-877
pubmed: 30721928
EMBO J. 1992 Nov;11(11):3887-95
pubmed: 1396582
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
Arch Pathol Lab Med. 2020 Nov 1;144(11):1392-1396
pubmed: 32150459
N Engl J Med. ;376(3):290-1
pubmed: 28102662
Nat Rev Drug Discov. 2016 Apr;15(4):235-47
pubmed: 26965203
N Engl J Med. 2019 Jun 13;380(24):2375-2376
pubmed: 31189042
Ann Oncol. 2020 Feb;31(2):171-190
pubmed: 31959335
Jpn J Clin Oncol. 2018 Jan 1;48(1):7-12
pubmed: 29045749
J Am Coll Cardiol. 2019 Oct 1;74(13):1714-1727
pubmed: 31558256
Circ J. 2020 Aug 25;84(9):1446-1453
pubmed: 32727978
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
Circulation. 2017 Nov 21;136(21):2085-2087
pubmed: 29158217
Nat Rev Cardiol. 2015 Jul;12(7):387-97
pubmed: 25855605
BMJ Case Rep. 2016 Jul 20;2016:
pubmed: 27440853
Circulation. 2020 Jun 16;141(24):2031-2034
pubmed: 32539614
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32245016
N Engl J Med. 2019 Jun 13;380(24):2377-2379
pubmed: 31189043
Nature. 1987 Jul 16-22;328(6127):267-70
pubmed: 3496540
Cell. 2018 Nov 29;175(6):1452-1454
pubmed: 30500529
Cardiovasc Res. 2019 Apr 15;115(5):854-868
pubmed: 30715219
Eur Heart J. 2020 May 7;41(18):1733-1743
pubmed: 32112560
JACC Cardiovasc Imaging. 2018 Aug;11(8):1187-1190
pubmed: 29550317
JAMA Oncol. 2019 Jul 1;5(7):1008-1019
pubmed: 31021376
J Immunol. 2008 Aug 15;181(4):2513-21
pubmed: 18684942
Eur J Heart Fail. 2019 Jul;21(7):945-947
pubmed: 31353808
Circulation. 2019 Jul 02;140(2):80-91
pubmed: 31390169
Int Immunol. 2010 Jun;22(6):443-52
pubmed: 20410257
Clin Rev Allergy Immunol. 2017 Jun;52(3):323-332
pubmed: 27342458
J Exp Med. 2000 Jul 17;192(2):303-10
pubmed: 10899917
Int J Cancer. 1971 Sep 15;8(2):185-91
pubmed: 4332366
Nat Rev Dis Primers. 2020 May 7;6(1):38
pubmed: 32382051
Lancet Oncol. 2018 Dec;19(12):1579-1589
pubmed: 30442497
J Am Coll Cardiol. 2017 Oct 17;70(16):1977-1987
pubmed: 29025554
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
Science. 1996 Mar 22;271(5256):1734-6
pubmed: 8596936